Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists
Public ClinicalTrials.gov record NCT00443872. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Adding Orally Disintegrating Selegiline (Zelapar) to Patients Taking Dopamine Agonists and Experiencing Complications
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to determine if reducing or eliminating a dopamine agonist (DA) causing one of the side effects of daytime sleepiness, swelling of the lower legs or feet, hallucinations or impulsive behaviors while adding orally disintegrating selegiline can eliminate the adverse effect and maintain control of Parkinson's disease (PD) symptoms.
Study identification
- NCT ID
- NCT00443872
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 77 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 30 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2007
- Primary completion
- Aug 31, 2008
- Completion
- Nov 30, 2008
- Last update posted
- Oct 30, 2014
2007 – 2008
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California - Irvine | Irvine | California | 92697 | — |
| Coastal Neurological Medical Group, Inc | La Jolla | California | 92037 | — |
| University of Southern California | Los Angeles | California | 90093 | — |
| The Parkinson's Institute | Sunnyvale | California | 94085 | — |
| Parkinson's Disease and Movement Disorder Center of Boca Raton | Boca Raton | Florida | 33486 | — |
| University of South Florida | Tampa | Florida | 33606 | — |
| Methodist Plaza Speciality Clinic | Des Moines | Iowa | 50309 | — |
| University of Kansas Medical Center | Kansas City | Kansas | 66160 | — |
| Ochsner Clinic Foundation | New Orleans | Louisiana | 70121 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Harvard Vanguard Medical Associates | Boston | Massachusetts | 02215 | — |
| Henry Ford Health Center - Franklin Pointe | Southfield | Michigan | 48034 | — |
| Struthers Parkinson's Center | Golden Valley | Minnesota | 55427 | — |
| University of Toledo | Toledo | Ohio | 43614 | — |
| NeuroHealth Parkinson Disease and Movement Disorder Center | Warwick | Rhode Island | 02886 | — |
| Neurology Specialists Dallas | Dallas | Texas | 75231 | — |
| ETMC Neurological Institute | Tyler | Texas | 75701 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00443872, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 30, 2014 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00443872 live on ClinicalTrials.gov.